Next Article in Journal
The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug–Drug Interactions: Drug–Gene, Drug–Gene–Gene and Drug–Drug–Gene Interactions
Previous Article in Journal
Synthesis of Novel Fluorinated Xanthine Derivatives with High Adenosine A2B Receptor Binding Affinity
Previous Article in Special Issue
Design of Topical Ocular Ciprofloxacin Nanoemulsion for the Management of Bacterial Keratitis
Article

Hydrotalcite–Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections

1
Intelligent Nanohybrid Materials Laboratory (INML), Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan 31116, Korea
2
College of Science and Technology, Dankook University, Cheonan 31116, Korea
3
Department of Nanobiomedical Science and BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan 31116, Korea
4
Department of Chemistry, College of Science and Technology, Dankook University, Cheonan 31116, Korea
5
R&D Center, CnPharm Co., Ltd., Seoul 03759, Korea
6
Department of Pre-medical Course, College of Medicine, Dankook University, Cheonan 31116, Korea
7
Tokyo Tech World Research Hub Initiative (WRHI), Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8503, Japan
*
Authors to whom correspondence should be addressed.
Academic Editor: Dimitris Tsiourvas
Pharmaceuticals 2021, 14(5), 486; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14050486
Received: 1 April 2021 / Revised: 8 May 2021 / Accepted: 14 May 2021 / Published: 19 May 2021
(This article belongs to the Special Issue Nano Drug Carriers 2021)
COVID-19 has been affecting millions of individuals worldwide and, thus far, there is no accurate therapeutic strategy. This critical situation necessitates novel formulations for already existing, FDA approved, but poorly absorbable drug candidates, such as niclosamide (NIC), which is of great relevance. In this context, we have rationally designed NIC-loaded hydrotalcite composite nanohybrids, which were further coated with Tween 60 or hydroxypropyl methyl cellulose (HPMC), and characterized them in vitro. The optimized nanohybrids showed particle sizes <300 nm and were orally administrated to rats to determine whether they could retain an optimum plasma therapeutic concentration of NIC that would be effective for treating COVID-19. The pharmacokinetic (PK) results clearly indicated that hydrotalcite-based NIC formulations could be highly potential options for treating the ongoing pandemic and we are on our way to understanding the in vivo anti-viral efficacy sooner. It is worth mentioning that hydrotalcite–NIC nanohybrids maintained a therapeutic NIC level, even above the required IC50 value, after just a single administration in 8–12 h. In conclusion, we were very successfully able to develop a NIC oral formulation by immobilizing with hydrotalcite nanoparticles, which were further coated with Tween 60 or HPMC, in order to enhance their emulsification in the gastrointestinal tract. View Full-Text
Keywords: niclosamide; hydrotalcite; nanohybrid; oral formulation; COVID-19; pharmacokinetics niclosamide; hydrotalcite; nanohybrid; oral formulation; COVID-19; pharmacokinetics
Show Figures

Figure 1

MDPI and ACS Style

Choi, G.; Piao, H.; Rejinold, N.S.; Yu, S.; Kim, K.-y.; Jin, G.-w.; Choy, J.-H. Hydrotalcite–Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections. Pharmaceuticals 2021, 14, 486. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14050486

AMA Style

Choi G, Piao H, Rejinold NS, Yu S, Kim K-y, Jin G-w, Choy J-H. Hydrotalcite–Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections. Pharmaceuticals. 2021; 14(5):486. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14050486

Chicago/Turabian Style

Choi, Goeun, Huiyan Piao, N. S. Rejinold, Seungjin Yu, Ki-yeok Kim, Geun-woo Jin, and Jin-Ho Choy. 2021. "Hydrotalcite–Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections" Pharmaceuticals 14, no. 5: 486. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14050486

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop